Generate a tailored SOP for Dr. Carl June. Improve your application with a focused, well-structured draft.
Carl June is a pioneer in cancer cell therapy, particularly known for his groundbreaking work in developing chimeric antigen receptor T-cell therapy (CAR-T therapy). He is a Richard W. Vague Professor of Immunotherapy at the Perelman School of Medicine at the University of Pennsylvania and the director of the Center for Cellular Immunotherapies at Penn Medicine’s Abramson Cancer Center. His innovations in genetically modifying T-cells have led to FDA-approved treatments for over 45,000 cancer patients suffering from previously incurable blood cancers including leukemia, lymphoma, and multiple myeloma. Dr. June's work has fundamentally changed cancer care, enabling the use of patients' own immune systems to target and kill cancer cells, thereby creating new avenues for therapies against solid tumors and autoimmune diseases. He has received numerous prestigious awards, including the 2024 Breakthrough Prize in Life Sciences and the 2021 Dan David Prize Laureate, recognizing his contributions to medicine and the field of immunotherapy. His research continues to spur advancements in engineered cell therapies and has significantly impacted academic and industrial efforts within the biomedical community.
Perelman School of Medicine, University of Pennsylvania • Philadelphia, PA
For leading the direction of clinical and translational research in cellular therapies and cancer immunotherapy.
Wharton Doctoral programs cover fields like Finance, Marketing, Management, and Operations, Information and Decisions.